@techreport{Grossmann2011cost,
abstract = {This paper examines the role of both cost-sharing schemes in health insurance systems and entry regulation for pharmaceutical R&D expenditure, drug prices, aggregate productivity, and income. The analysis suggests that both an increase in the coinsurance rate and stricter price regulations adversely affect R&D spending in the pharmaceutical sector. In contrast, entry deregulation may lead to quality-improvements of pharmaceuticals, despite reducing price-setting power of pharmaceutical companies. Extension to an endogenous growth context suggests that, when individual labor supply depends on health status, both cost-sharing and entry barriers in the pharmaceutical sector also affect aggregate productivity and wage rates.},
address = {M\"{u}nchen},
author = {Volker Grossmann},
copyright = {http://www.econstor.eu/dspace/Nutzungsbedingungen},
keywords = {I10; L10; O30; 330; aggregate productivity; cost-sharing; entry deregulation; health insurance; pharmaceutical innovation; Pharmazeutische Forschung; Forschungsfinanzierung; Kostenbeteiligung; Gesetzliche Krankenversicherung; Markteintritt; Gesundheits\"{o}konomik; Produktivit\"{a}t; Neue Wachstumstheorie; Theorie},
language = {eng},
number = {3439},
publisher = {CESifo},
title = {Do cost-sharing and entry deregulation curb pharmaceutical Innovation?},
type = {CESifo working paper: Public Finance},
url = {http://hdl.handle.net/10419/46570},
year = {2011}
}
